ImmunityBio (NASDAQ:IBRX) Hits New 52-Week High – Here’s What Happened

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) hit a new 52-week high on Thursday . The stock traded as high as $8.28 and last traded at $7.2680, with a volume of 34566229 shares traded. The stock had previously closed at $6.92.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA meeting gave a defined path to resubmit an sBLA for ANKTIVA and ImmunityBio said it will file additional information within 30 days — a direct regulatory catalyst supporting upside. FDA Talks Set Path For Expanded Use For ImmunityBio’s Anktiva In Bladder Cancer
• Positive Sentiment: H.C. Wainwright reiterated bullish coverage and raised long?term estimates (FY2030 EPS outlook increased), signaling growing analyst confidence that supports investor interest. H.C. Wainwright Affirms Buy Rating for ImmunityBio
• Positive Sentiment: Multiple broker notes and “buy” ratings with higher targets have circulated in recent days, reinforcing speculative buying and momentum among retail/long investors. MarketBeat IBRX Coverage
• Neutral Sentiment: Short sellers are being pressured by the rapid run-up, which can accelerate moves via forced covering but is a technical, not fundamental, support for the rally. Stock Market Today: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: The share price has run for multiple sessions (reported as a 12?day streak in some outlets) and much of today’s upside reflects momentum and heavy volume rather than new clinical trial results. ImmunityBio rockets on 12th day
• Negative Sentiment: Insiders have sold shares recently — director Christobel Selecky sold 25,000 shares at ~$7.51 (and previously 50,000 at ~$5), and director Barry J. Simon sold ~151,967 shares — actions investors often interpret as profit?taking or diversification. ImmunityBio Director Sells Stock
• Negative Sentiment: Prominent commentators (e.g., Jim Cramer) have advised taking profits amid the froth, highlighting momentum risk and the chance that regulatory follow?ups could require more time/data than the market expects. Jim Cramer on ImmunityBio

Analyst Ratings Changes

A number of analysts recently weighed in on IBRX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Piper Sandler increased their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of ImmunityBio in a research report on Tuesday. Finally, Jefferies Financial Group boosted their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, ImmunityBio has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

ImmunityBio Stock Up 3.0%

The company has a market capitalization of $7.02 billion, a PE ratio of -17.33 and a beta of 0.03. The business has a 50 day simple moving average of $2.54 and a 200 day simple moving average of $2.52.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. The company had revenue of $32.06 million for the quarter, compared to analyst estimates of $31.88 million. Equities analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 151,967 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the transaction, the director owned 3,091,604 shares in the company, valued at approximately $22,259,548.80. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 226,967 shares of company stock valued at $1,531,912. 69.48% of the stock is owned by company insiders.

Institutional Trading of ImmunityBio

Several institutional investors have recently bought and sold shares of IBRX. Slow Capital Inc. purchased a new stake in ImmunityBio in the 3rd quarter worth $25,000. Envision Financial Planning LLC acquired a new stake in shares of ImmunityBio in the second quarter valued at about $28,000. Summit X LLC purchased a new stake in shares of ImmunityBio during the second quarter worth about $28,000. Diversify Advisory Services LLC acquired a new position in shares of ImmunityBio during the 2nd quarter worth about $27,000. Finally, Truist Financial Corp purchased a new position in ImmunityBio in the 3rd quarter valued at about $27,000. 8.58% of the stock is owned by institutional investors and hedge funds.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.